Private Capital Advisors Inc. Boosts Stake in iShares NASDAQ Biotechnology Index (IBB)

Private Capital Advisors Inc. raised its stake in shares of iShares NASDAQ Biotechnology Index (NASDAQ:IBB) by 973.1% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 19,433 shares of the financial services provider’s stock after acquiring an additional 17,622 shares during the period. Private Capital Advisors Inc.’s holdings in iShares NASDAQ Biotechnology Index were worth $2,075,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. CHURCHILL MANAGEMENT Corp raised its stake in iShares NASDAQ Biotechnology Index by 223.2% during the 4th quarter. CHURCHILL MANAGEMENT Corp now owns 1,801,330 shares of the financial services provider’s stock valued at $192,328,000 after acquiring an additional 1,244,066 shares during the last quarter. Clal Insurance Enterprises Holdings Ltd raised its stake in iShares NASDAQ Biotechnology Index by 175.5% during the 3rd quarter. Clal Insurance Enterprises Holdings Ltd now owns 635,875 shares of the financial services provider’s stock valued at $212,132,000 after acquiring an additional 405,091 shares during the last quarter. Quantitative Investment Management LLC purchased a new position in shares of iShares NASDAQ Biotechnology Index during the 2nd quarter worth approximately $103,504,000. Ameriprise Financial Inc. raised its stake in shares of iShares NASDAQ Biotechnology Index by 9.3% during the 3rd quarter. Ameriprise Financial Inc. now owns 101,917 shares of the financial services provider’s stock worth $33,991,000 after buying an additional 8,667 shares in the last quarter. Finally, Williams Jones & Associates LLC raised its stake in shares of iShares NASDAQ Biotechnology Index by 91.0% during the 2nd quarter. Williams Jones & Associates LLC now owns 92,556 shares of the financial services provider’s stock worth $28,700,000 after buying an additional 44,096 shares in the last quarter. 21.10% of the stock is owned by hedge funds and other institutional investors.

Shares of iShares NASDAQ Biotechnology Index (NASDAQ:IBB) traded up $0.75 during mid-day trading on Friday, hitting $111.98. The stock had a trading volume of 2,200,000 shares, compared to its average volume of 2,350,000. The stock has a market cap of $10,360.00, a P/E ratio of 3.70 and a beta of 1.38. iShares NASDAQ Biotechnology Index has a fifty-two week low of $88.96 and a fifty-two week high of $114.17.

The firm also recently announced a quarterly dividend, which was paid on Thursday, December 28th. Stockholders of record on Friday, December 22nd were paid a dividend of $0.125 per share. This represents a $0.50 dividend on an annualized basis and a dividend yield of 0.45%. This is an increase from iShares NASDAQ Biotechnology Index’s previous quarterly dividend of $0.04. The ex-dividend date was Thursday, December 21st. iShares NASDAQ Biotechnology Index’s dividend payout ratio is 2.38%.

ILLEGAL ACTIVITY NOTICE: “Private Capital Advisors Inc. Boosts Stake in iShares NASDAQ Biotechnology Index (IBB)” was originally reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://ledgergazette.com/2018/01/12/private-capital-advisors-inc-boosts-stake-in-ishares-nasdaq-biotechnology-index-ibb.html.

About iShares NASDAQ Biotechnology Index

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares NASDAQ Biotechnology Index (NASDAQ:IBB).

Institutional Ownership by Quarter for iShares NASDAQ Biotechnology Index (NASDAQ:IBB)

Receive News & Ratings for iShares NASDAQ Biotechnology Index Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares NASDAQ Biotechnology Index and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply